Terms: = Skin cancer AND CCND2, KIAK0002, 894, ENSG00000118971, P30279, MGC102758 AND Treatment
12 results:
1. Survivals following discontinuation of PD-1 inhibitor treatment in advanced melanoma patients.
Kartolo A; Tong J; Yeung C; Kuksis M; Hopman W; Baetz T
Melanoma Res; 2023 Feb; 33(1):50-57. PubMed ID: 36382411
[TBL] [Abstract] [Full Text] [Related]
2. Concurrent Chemoradiation Therapy With or Without Nimotuzumab in Locally Advanced Squamous Cell Lung cancer: A Phase 2 Randomized Trial.
Qiu B; Wang D; Li Q; Wu Y; Guo S; Jiang X; Fang J; Guo J; Liu F; Chu C; Wang B; Chen L; Zhang J; Liu Y; Hu Y; Liu H
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(4):917-925. PubMed ID: 34229051
[TBL] [Abstract] [Full Text] [Related]
3. Cutaneous Manifestations of EGFR-Inhibitors in African Americans and treatment Considerations.
Geisler AN; Noor SJ
J Drugs Dermatol; 2020 Sep; 19(9):894-896. PubMed ID: 33026750
[TBL] [Abstract] [Full Text] [Related]
4. Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy.
Kartolo A; Holstead R; Khalid S; Emack J; Hopman W; Robinson A; Baetz T
Immunotherapy; 2020 Aug; 12(11):785-798. PubMed ID: 32657234
[No Abstract] [Full Text] [Related]
5. An Analysis of 1-Year Charges for Head and Neck cancer: Targets for Value-Based Interventions.
Pang J; Crawford K; Faraji F; Ramsey C; Kemp A; Califano JA
Otolaryngol Head Neck Surg; 2020 Sep; 163(3):546-553. PubMed ID: 32450778
[TBL] [Abstract] [Full Text] [Related]
6. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
Dreno B; Thompson JF; Smithers BM; Santinami M; Jouary T; Gutzmer R; Levchenko E; Rutkowski P; Grob JJ; Korovin S; Drucis K; Grange F; Machet L; Hersey P; Krajsova I; Testori A; Conry R; Guillot B; Kruit WHJ; Demidov L; Thompson JA; Bondarenko I; Jaroszek J; Puig S; Cinat G; Hauschild A; Goeman JJ; van Houwelingen HC; Ulloa-Montoya F; Callegaro A; Dizier B; Spiessens B; Debois M; Brichard VG; Louahed J; Therasse P; Debruyne C; Kirkwood JM
Lancet Oncol; 2018 Jul; 19(7):916-929. PubMed ID: 29908991
[TBL] [Abstract] [Full Text] [Related]
7. Anti-Tumor Necrosis Factor-α-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients.
Andrade P; Lopes S; Gaspar R; Nunes A; Magina S; Macedo G
Dig Dis Sci; 2018 Mar; 63(3):746-754. PubMed ID: 29349693
[TBL] [Abstract] [Full Text] [Related]
8. Identification of anaplastic lymphoma kinase as a potential therapeutic target in Basal Cell Carcinoma.
Ning H; Mitsui H; Wang CQ; Suárez-Fariñas M; Gonzalez J; Shah KR; Chen J; Coats I; Felsen D; Carucci JA; Krueger JG
Oncotarget; 2013 Dec; 4(12):2237-48. PubMed ID: 24163262
[TBL] [Abstract] [Full Text] [Related]
9. Loop ileostomy versus loop colostomy for fecal diversion after colorectal or coloanal anastomosis: a meta-analysis.
Rondelli F; Reboldi P; Rulli A; Barberini F; Guerrisi A; Izzo L; Bolognese A; Covarelli P; Boselli C; Becattini C; Noya G
Int J Colorectal Dis; 2009 May; 24(5):479-88. PubMed ID: 19219439
[TBL] [Abstract] [Full Text] [Related]
10. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
Zhu AX; Clark JW; Ryan DP; Meyerhardt JA; Enzinger PC; Earle CC; Fuchs CS; Regan E; Anbe H; Houghton M; Zhang J; Urrea P; Kulke MH
Cancer Chemother Pharmacol; 2007 Feb; 59(3):285-93. PubMed ID: 16786333
[TBL] [Abstract] [Full Text] [Related]
11. An alarming lack of public awareness towards oral cancer.
Warnakulasuriya KA; Harris CK; Scarrott DM; Watt R; Gelbier S; Peters TJ; Johnson NW
Br Dent J; 1999 Sep; 187(6):319-22. PubMed ID: 10589135
[TBL] [Abstract] [Full Text] [Related]
12. Environmental factors and the risk of salivary gland cancer.
Horn-Ross PL; Ljung BM; Morrow M
Epidemiology; 1997 Jul; 8(4):414-9. PubMed ID: 9209856
[TBL] [Abstract] [Full Text] [Related]
